Semaglutide or tirzepatide —
know before you decide.
Free calculators, real India pricing, and doctor-reviewed answers about GLP-1 weight loss — so you can walk into a doctor's clinic already informed.
Start here. Understand eligibility, cost, timeline and side effects before you talk to a doctor.
Manage side effects, protect muscle, break plateaus, and plan your off-ramp — the smart way.
Free calculators
Six quick tools. No signup. Built for India.
See if a GLP-1 plan may be right for you — in 2 minutes.
India-adjusted BMI with what it actually means for you.
Real monthly cost of semaglutide vs tirzepatide in India.
Realistic weight-loss curve, month by month.
Is that side effect normal — or a red flag?
Practical tips to reduce nausea, fatigue and plateaus.
Popular questions
When prescribed and monitored by a doctor, yes — but dosing, diet and monitoring differ from Western protocols.
Tirzepatide typically drives more weight loss, but costs more and isn't right for everyone. It's a doctor's call.
Roughly ₹17,000–₹26,000/month depending on molecule, dose and brand. Use our cost calculator.
Read & relate
Stories and explainers for real people, not textbooks.
Why GLP-1s changed the conversation for people with type 2 diabetes.
A realistic plan for busy professionals who've tried everything.
Ozempic face, muscle loss, rebound weight — what's true, what's not.
Latest updates
What's new in India's GLP-1 landscape.
Monthly GLP-1 drug sales in India grew just 2.3% in June 2026, down sharply from 58.4% growth in April, according to market research firm Pharmarack. The rush that followed March's patent expiry appears to be settling into a steadier, more considered adoption curve rather than continuing to accelerate.
Dr Reddy's Laboratories became the first company to offer an oral semaglutide tablet in India, branded Obeda, priced at ₹99, ₹135 and ₹225 for the 3mg, 7mg and 14mg doses respectively. The company also sells an injectable version of Obeda in a pre-filled pen at roughly ₹4,200 a month.
The Indian government issued national guidelines restricting GLP-1 prescriptions to endocrinologists, internal medicine specialists and cardiologists — these medicines cannot be bought over the counter. A related advisory cracked down on misleading advertising, and dozens of pharmacies, wholesalers and weight-loss clinics were inspected for unauthorised sales.